Xromi obtained marketing-authorisation for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 2 years of age
In April 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xromi. It is a medicine used in adults, adolescents and children over two years of age who have sickle cell disease, a genetic disease where the red blood